TYZAVAN Trademark

Trademark Overview

On Wednesday, August 2, 2023, a trademark application was filed for TYZAVAN with the United States Patent and Trademark Office. The USPTO has given the TYZAVAN trademark a serial number of 98113173. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Tuesday, January 6, 2026. This trademark is owned by Xellia Pharmaceuticals ApS. The TYZAVAN trademark is filed in the Pharmaceutical Products category with the following description:

Anti-infective, injectable pharmaceutical products in liquid finished dosage form for use in hospitals and clinics or by home health care professionals
tyzavan

General Information

Serial Number98113173
Word MarkTYZAVAN
Filing DateWednesday, August 2, 2023
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateTuesday, January 6, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 14, 2024

Trademark Statements

Translation of Words in MarkThe wording "TYZAVAN" has no meaning in a foreign language.
Goods and ServicesAnti-infective, injectable pharmaceutical products in liquid finished dosage form for use in hospitals and clinics or by home health care professionals

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 7, 2023
Primary Code005
First Use Anywhere DateFriday, June 27, 2025
First Use In Commerce DateMonday, December 8, 2025

Trademark Owner History

Party NameHIKMA PHARMACEUTICALS USA INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressBERKELEY HEIGHTS, NJ 07922
Party NameXellia Pharmaceuticals ApS
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCopenhagen S 2300
DK
Party NameXellia Pharmaceuticals ApS
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCopenhagen S 2300
DK

Trademark Events

Event DateEvent Description
Saturday, August 5, 2023NEW APPLICATION ENTERED
Monday, August 7, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 5, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, January 5, 2024TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Wednesday, April 3, 2024ASSIGNED TO EXAMINER
Thursday, April 4, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, April 4, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, April 4, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, April 4, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, April 4, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 14, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 14, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 9, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 19, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 19, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, November 19, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 8, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, February 12, 2025AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, April 14, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, January 8, 2025SOU EXTENSION 1 FILED
Wednesday, April 16, 2025SOU EXTENSION 1 GRANTED
Thursday, April 17, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 7, 2025SOU TEAS EXTENSION RECEIVED
Monday, July 7, 2025SOU EXTENSION 2 FILED
Monday, July 7, 2025SOU EXTENSION 2 GRANTED
Tuesday, July 8, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 30, 2025TEAS STATEMENT OF USE RECEIVED
Tuesday, December 30, 2025USE AMENDMENT FILED
Friday, January 2, 2026STATEMENT OF USE PROCESSING COMPLETE
Tuesday, January 6, 2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, January 6, 2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

tyzavan hospitals form clinics health professionals care dosage finished injectable infective